Sign up USA
Proactive Investors - Run By Investors For Investors

Zogenix shares pop on impressive Phase 3 results for epilepsy drug

The biotech's experimental drug ZX008 reduced the frequency of convulsive seizures in Phase 3 trial
lab technician with test tubes
Zogenix shares jumped 19% in pre-market trade

Zogenix Inc shares (NASDAQ:ZGNX) rocketed in the pre-market session after the biotech revealed that its drug to treat Dravet syndrome, a severe form of epilepsy, reduced the frequency of convulsive seizures that stem from the disease.

Before the opening bell, Zogenix shares jumped 19% to US$55.05 in response to the news.

Zogenix said that its Phase 3 study for its experimental drug ZX008 (low-dose flenfluramine hydrochloride) which treats children and young adults with Dravet syndrome successfully met its primary endpoint and all key secondary endpoints.

Indeed, patients in the study who took ZX008 reported a 54.7% reduction in mean monthly convulsive seizures compared to those who took a placebo.

Read: Zogenix achieves meaningful seizure control in latest tests

“These impressive study results show the significant impact the addition of ZX008 made in reducing the burden of convulsive seizures for patients who are not adequately controlled using stiripentol, the standard of care for the treatment of Dravet syndrome in Europe,” said Dr. Rima Nabbout , an investigator for the study who works in the department of pediatric neurology with Necker Enfants Malades Hospital.

“If approved, ZX008 has the potential to be a transformative treatment for Dravet syndrome, a rare and serious form of epilepsy with few available treatment options,” she added.

ZX008 was also generally well-tolerated in this study, which evaluated 87 epileptic patients, ranging in age from 2 to 19.

A few of the most common side-effects endured were decreased appetite, diarrhea and fatigue.

The company is now set to submit applications for marketing approvals of the drug in both the US and Europe later this year.

ZX008 is already designated as an orphan drug in the US and Europe and has received recognition as a breakthrough therapy in the US for the treatment of Dravet syndrome.

View full ZGNX profile View Profile

Zogenix Timeline

Related Articles

picture of cannabis plants
March 23 2018
Control of the supply chain offers operational advantages and financial benefits.
lab
March 15 2018
Amryt's lead drug candidate, AP101, is a potential treatment for epidermolysis bullosa, a rare genetic skin disorder for which there is currently no approved treatment
Vial of pills
June 25 2018
Cosmos is a modern company, but the trade routes it relies on are ancient

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use